Our onco-metabolism approach brings
an enhanced perspective to cancer.
- Company
- Science
- Programs
- Clinical Trials
- Media & Investors
- Financial Information
- Corporate Governance
- Shareholder Services
-
Calithera Biosciences to Participate in the Citi 13th Annual Biotech Conference and the Wells Fargo Healthcare Conference
-
Calithera Biosciences Reports Second Quarter 2018 Financial Results and Recent Highlights
-
Calithera Biosciences to Report Second Quarter 2018 Financial Results on Tuesday, August 7, 2018
-
Calithera to Present at the Jefferies and JMP Securities Healthcare Conferences in June
-
Results from Phase 1 Study of CB-839 in Combination with Capecitabine in Advanced Solid Tumors to be Presented at the 2018 American Society of Clinical Oncology (ASCO)
Development Pipeline
Calithera is committed to discovering and developing first-in-class small molecule drugs to fight tumor metabolism and tumor immunology targets differently – and to make a difference for patients.
Recent News
- Shareholder Services
- Corporate Governance
- Financial Information
- Media & Investors
- Clinical Trials
- Programs
- Science
